These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24267634)

  • 1. Subcutaneous DMPA: a better lower dose approach.
    Shelton JD; Halpern V
    Contraception; 2014 May; 89(5):341-3. PubMed ID: 24267634
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous depo-medroxyprogesterone acetate.
    Cameron S
    J Fam Plann Reprod Health Care; 2013 Apr; 39(2):75-7. PubMed ID: 23493590
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contraception 2000: lunelle, an injectable combination contraceptive option.
    Shulman LP
    J Womens Health Gend Based Med; 2000 Sep; 9(7):725-9. PubMed ID: 11025864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraceptive efficacy and safety of DMPA-SC.
    Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
    Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
    Cameron ST; Glasier A; Johnstone A
    Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DMPA-SC: an emerging option to increase women's contraceptive choices.
    Askew I; Wells E
    Contraception; 2018 Nov; 98(5):375-378. PubMed ID: 30145126
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
    Westhoff C; Jain JK; Milsom I; Ray A
    Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of depot medroxyprogesterone acetate contraception.
    Mishell DR
    J Reprod Med; 1996 May; 41(5 Suppl):381-90. PubMed ID: 8725700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.
    Halpern V; Combes SL; Dorflinger LJ; Weiner DH; Archer DF
    Contraception; 2014 Jan; 89(1):31-5. PubMed ID: 23993431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The members' enquiry service: frequently asked questions.
    de Souza A; Brechin S; Penney G;
    J Fam Plann Reprod Health Care; 2004 Jan; 30(1):57-8. PubMed ID: 15006318
    [No Abstract]   [Full Text] [Related]  

  • 12. Painless Depo-medroxyprogesterone acetate (DMPA) injections using the 'pinch technique'.
    Fletcher H
    J Obstet Gynaecol; 2004 Aug; 24(5):562-3. PubMed ID: 15369941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.
    Segall-Gutierrez P; Taylor D; Liu X; Stanzcyk F; Azen S; Mishell DR
    Contraception; 2010 Jun; 81(6):487-95. PubMed ID: 20472115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
    Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
    Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sayana® Press: can it be a "game changer" for reducing unmet need for family planning?
    Spieler J
    Contraception; 2014 May; 89(5):335-8. PubMed ID: 24703826
    [No Abstract]   [Full Text] [Related]  

  • 17. Merits of DMPA relative to other reversible contraceptive methods.
    Nelson A
    J Reprod Med; 2002 Sep; 47(9 Suppl):781-4. PubMed ID: 12380406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.
    Burke HM; Mueller MP; Packer C; Perry B; Bufumbo L; Mbengue D; Daff BM; Mbonye A
    Contraception; 2014 May; 89(5):368-73. PubMed ID: 24576792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
    Prabhakaran S; Sweet A
    Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
    Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
    Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.